Sensorion Azione

Sensorion PEG

PEG Ratio (Rapporto prezzo-utile-crescita) di Sensorion (ALSEN.PA) al 13 ago 2026.

PEG

0,00

Ultimo aggiornamento:

PEG Ratio (Rapporto prezzo-utile-crescita) di Sensorion ammonta a 2026 0,00 . PEG Ratio (Rapporto prezzo-utile-crescita) di Sensorion ammontava a 2025 -0,11 . Diminuisce del % superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Sensorion Analisi delle Azioni

Cosa fa Sensorion? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Sensorion azioni

Su Eulerpool è possibile consultare lo sviluppo storico completo del Sensorion di PEG Ratio (Rapporto prezzo-utile-crescita) dal 2006, con valori annuali, grafici e analisi dettagliate.

Il rapporto PEG rettifica il P/E in base al tasso di crescita atteso dei guadagni. Un PEG inferiore a 1 può indicare un'azione sottovalutata rispetto al suo potenziale di crescita.

PEG = Rapporto P/E / Tasso di crescita annuale atteso dell'EPS

Per valutare di PEG Ratio (Rapporto prezzo-utile-crescita), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per PEG Ratio (Rapporto prezzo-utile-crescita).

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Sensorion di PEG Ratio (Rapporto prezzo-utile-crescita) con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Valutazione — Sensorion

Tutte le Metriche Finanziarie — Sensorion